Odyral (Dorzolamide)

Dorzolamide, the active ingredient in Odyral, is a carbonic anhydrase inhibitor presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of glaucoma and ocular hypertension in adult patients and can be used as adjunct therapy.

GNH USA supplies Odyral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution in multiple jurisdictions. Customers benefit from reliable lead times and dedicated technical support.

Dorzolamide is used to reduce intra‑ocular pressure in several glaucoma‑related conditions.

- Open‑angle glaucoma: reduces intra‑ocular pressure, helping to preserve visual field and slow disease progression. - Ocular hypertension: lowers pressure to prevent development of glaucoma. - Secondary glaucoma: helps control pressure when elevated due to other ocular disorders.

Dorzolamide may cause ocular and systemic adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects: - Eye irritation or discomfort: mild burning or stinging after instillation. - Blurred vision: temporary reduction in visual clarity. - Taste disturbance: bitter taste sensation. - Headache: mild to moderate.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or anaphylaxis. - Corneal edema: swelling of the cornea affecting vision. - Persistent ocular pain: prolonged discomfort requiring medical review.

When using Odyral, consider the following precautions.

- Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown; consider potential risk to infant. - Renal impairment: monitor renal function as the drug is eliminated renally. - Concurrent ocular surgery: discontinue prior to procedure to avoid wound healing complications. - Allergy: avoid if known hypersensitivity to dorzolamide or sulfonamides. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive effect may cause excessive intra‑ocular pressure lowering. - Topical beta‑blockers: combined use may increase risk of ocular hypotension. - Sulfonamide antibiotics: cross‑reactivity may trigger allergic response.

Moderate Interactions (Monitor Closely): - Topical prostaglandin analogues: may affect efficacy; monitor pressure. - Systemic diuretics: may alter electrolyte balance; observe renal function. - Anticholinergic eye drops: possible reduced drug absorption.